Table 3.
Recommended therapy for suspected or confirmed multidrug resistant organisms and fungal VAP [1], [34], [35], [41]
| Pathogen | Treatment |
|---|---|
| Methicillin-resistant Staphylococcus aureus (MRSA) | See Table 2 |
| Pseudomonas aeruginosa | Double coverage recommended. See Table 2 |
| Acinetobacter species | Carbapenem |
| e. g., imipenem + cilastin; 1 g every 8 hours; | |
| meropenem 1 g every 8 hours | |
| OR | |
| Beta-Lactam/beta-lactamase inhibitor | |
| e. g., ampicillin + sulbactam: 3 g every 8 | |
| hours | |
| OR | |
| Tigecycline: 100 mg loading dose, then 50 mg every 12 hours | |
| Extended-spectrum beta-lactamase (ESBL) positive enterobacteriaceae | Carbepenem |
| e. g., imipenem + cilastin: 1 g every 8 hours; | |
| meropenem: 1 g every 8 hours | |
| Fungi | Fluconazole: 800 mg every 12 hours; |
| caspofungin: 70 mg loading dose, then 50 mg daily; | |
| voriconazole (for aspergillus species): 4 mg/kg every 12 hours | |
| Legionella | Macrolides (e. g., azithromycin) |
| OR | |
| Fluoroquinolones (e. g., levofloxacin) |